IL266962B - Heteroarylphenoxy benzamide kappa opioid ligands, preparations containing them and their uses - Google Patents
Heteroarylphenoxy benzamide kappa opioid ligands, preparations containing them and their usesInfo
- Publication number
- IL266962B IL266962B IL266962A IL26696219A IL266962B IL 266962 B IL266962 B IL 266962B IL 266962 A IL266962 A IL 266962A IL 26696219 A IL26696219 A IL 26696219A IL 266962 B IL266962 B IL 266962B
- Authority
- IL
- Israel
- Prior art keywords
- heteroarylphenoxy
- benzamide
- compositions
- same
- kappa opioid
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
- 239000003446 ligand Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426980P | 2016-11-28 | 2016-11-28 | |
| US201762576435P | 2017-10-24 | 2017-10-24 | |
| US201762585016P | 2017-11-13 | 2017-11-13 | |
| PCT/IB2017/057418 WO2018096510A1 (en) | 2016-11-28 | 2017-11-27 | Heteroarylphenoxy benzamide kappa opioid ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL266962A IL266962A (en) | 2019-07-31 |
| IL266962B true IL266962B (en) | 2022-02-01 |
Family
ID=60782279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL266962A IL266962B (en) | 2016-11-28 | 2019-05-28 | Heteroarylphenoxy benzamide kappa opioid ligands, preparations containing them and their uses |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10316021B2 (enExample) |
| EP (1) | EP3544972B8 (enExample) |
| JP (1) | JP7051853B2 (enExample) |
| CN (1) | CN110234638B (enExample) |
| AU (1) | AU2017365123B2 (enExample) |
| DK (1) | DK3544972T3 (enExample) |
| ES (1) | ES2947293T3 (enExample) |
| FI (1) | FI3544972T3 (enExample) |
| HR (1) | HRP20230518T1 (enExample) |
| HU (1) | HUE061945T2 (enExample) |
| IL (1) | IL266962B (enExample) |
| MX (1) | MX389806B (enExample) |
| PH (1) | PH12019501172A1 (enExample) |
| PL (1) | PL3544972T3 (enExample) |
| PT (1) | PT3544972T (enExample) |
| RS (1) | RS64258B1 (enExample) |
| TW (1) | TWI720272B (enExample) |
| WO (1) | WO2018096510A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018154118A2 (en) * | 2017-02-24 | 2018-08-30 | Reinmueller Viktoria | Novel aromatic compounds |
| AU2018223177B2 (en) * | 2017-02-24 | 2024-05-02 | Xeniopro GmbH | Aromatic compounds which enhance notch signaling, for use in therapy |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN111233768B (zh) * | 2020-03-18 | 2021-08-03 | 徐州圣元化工有限公司 | 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法 |
| KR20210151949A (ko) * | 2020-04-05 | 2021-12-14 | 화이자 인코포레이티드 | Covid-19의 치료를 위한 화합물 및 방법 |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| TW202345795A (zh) * | 2022-03-07 | 2023-12-01 | 美商健生醫藥公司 | 純質形式之結晶型阿替卡普蘭 |
| US11998524B2 (en) * | 2022-03-07 | 2024-06-04 | Janssen Pharmaceuticals, Inc. | Forms of aticaprant |
| IL315415A (en) | 2022-03-07 | 2024-11-01 | Janssen Pharmaceuticals Inc | The compositions containing eticarpant |
| AR130742A1 (es) * | 2022-10-12 | 2025-01-15 | Adama Makhteshim Ltd | Proceso para la preparación de derivados de aminopiridazina |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| JP2000159747A (ja) | 1998-09-21 | 2000-06-13 | Takeda Chem Ind Ltd | 新規チオ―ル誘導体、その製造法および用途 |
| CA2344412A1 (en) | 1998-09-21 | 2000-03-30 | Takeda Chemical Industries, Ltd. | Thiol compound, their production and use |
| IT1303737B1 (it) | 1998-11-11 | 2001-02-23 | Smithkline Beecham Spa | Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1. |
| SI2208727T1 (sl) | 2002-09-19 | 2012-11-30 | Lilly Co Eli | Diaril etri kot antagonisti opioidnega receptorja |
| US7365209B2 (en) | 2003-02-11 | 2008-04-29 | Pharmacopeia, Inc. | Nitrogen heterocycle biaryls for osteoporosis and other diseases |
| BRPI0408108A (pt) | 2003-03-07 | 2006-03-01 | Lilly Co Eli | composto, composição farmacêutica, métodos para bloquear em receptor mu, kappa, delta ou uma combinação de receptores dos mesmos em um mamìfero, para tratar ou prevenir obesidade e doenças relacionadas e para suprimir apetite, e, uso de um composto |
| EP2385040A1 (en) | 2003-03-14 | 2011-11-09 | ONO Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| RU2416608C2 (ru) | 2004-08-06 | 2011-04-20 | Оцука Фармасьютикал Ко., Лтд. | Ароматическое соединение |
| CN101120055B (zh) | 2005-02-18 | 2014-07-23 | 日本曹达株式会社 | 有机无机复合体 |
| CA2644368A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| PT2001456E (pt) | 2006-04-04 | 2010-03-03 | Emodys Gmbh | Utilização de composições contendo antagonistas dos receptores opióides kappa no tratamento de distúrbios dissociativos |
| WO2009094260A1 (en) | 2008-01-22 | 2009-07-30 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| WO2009102893A2 (en) | 2008-02-14 | 2009-08-20 | Amira Pharmaceuticals, Inc. | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors |
| CR11559A (es) | 2008-03-25 | 2010-10-20 | Lilly Co Eli | Antagonista del receptor opioide selectivo kappa |
| US8048895B2 (en) | 2008-04-18 | 2011-11-01 | Research Triangle Institute | Kappa opioid receptor ligands |
| EP2361248B1 (en) | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| EP2379524A1 (en) | 2008-12-18 | 2011-10-26 | Boehringer Ingelheim International GmbH | Serotonin 5-ht2b receptor inhibitors |
| HN2010001319A (es) | 2009-01-26 | 2013-01-15 | Lilly Co Eli | Antagonista del receptor opioide selectivo kappa |
| WO2013059648A1 (en) | 2011-10-21 | 2013-04-25 | Neurotherapeutics Pharma, Inc. | 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use |
| CN104684894A (zh) | 2012-10-02 | 2015-06-03 | 默克专利股份有限公司 | 吡咯烷类 |
| WO2015109080A1 (en) | 2014-01-15 | 2015-07-23 | Research Triangle Institute | Kappa-opioid receptor selective opioid receptor antagonists |
| WO2016086149A1 (en) | 2014-11-26 | 2016-06-02 | University Of Kansas | Antagonists of the kappa opioid receptor |
-
2017
- 2017-11-22 US US15/820,679 patent/US10316021B2/en active Active
- 2017-11-27 WO PCT/IB2017/057418 patent/WO2018096510A1/en not_active Ceased
- 2017-11-27 MX MX2019006220A patent/MX389806B/es unknown
- 2017-11-27 HR HRP20230518TT patent/HRP20230518T1/hr unknown
- 2017-11-27 PL PL17818281.2T patent/PL3544972T3/pl unknown
- 2017-11-27 HU HUE17818281A patent/HUE061945T2/hu unknown
- 2017-11-27 AU AU2017365123A patent/AU2017365123B2/en active Active
- 2017-11-27 RS RS20230453A patent/RS64258B1/sr unknown
- 2017-11-27 PT PT178182812T patent/PT3544972T/pt unknown
- 2017-11-27 JP JP2019528746A patent/JP7051853B2/ja active Active
- 2017-11-27 FI FIEP17818281.2T patent/FI3544972T3/fi active
- 2017-11-27 EP EP17818281.2A patent/EP3544972B8/en active Active
- 2017-11-27 CN CN201780084763.0A patent/CN110234638B/zh active Active
- 2017-11-27 TW TW106141134A patent/TWI720272B/zh active
- 2017-11-27 DK DK17818281.2T patent/DK3544972T3/da active
- 2017-11-27 ES ES17818281T patent/ES2947293T3/es active Active
-
2019
- 2019-05-28 IL IL266962A patent/IL266962B/en unknown
- 2019-05-28 PH PH12019501172A patent/PH12019501172A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180148432A1 (en) | 2018-05-31 |
| US10316021B2 (en) | 2019-06-11 |
| JP2019535799A (ja) | 2019-12-12 |
| EP3544972A1 (en) | 2019-10-02 |
| WO2018096510A1 (en) | 2018-05-31 |
| ES2947293T3 (es) | 2023-08-04 |
| CA3045242A1 (en) | 2018-05-31 |
| EP3544972B8 (en) | 2023-06-07 |
| PL3544972T3 (pl) | 2023-07-24 |
| JP7051853B2 (ja) | 2022-04-11 |
| IL266962A (en) | 2019-07-31 |
| HRP20230518T1 (hr) | 2023-08-04 |
| PH12019501172A1 (en) | 2019-12-11 |
| NZ754862A (en) | 2024-11-29 |
| AU2017365123A1 (en) | 2019-07-11 |
| TW201831460A (zh) | 2018-09-01 |
| DK3544972T3 (da) | 2023-05-30 |
| EP3544972B1 (en) | 2023-04-26 |
| RS64258B1 (sr) | 2023-07-31 |
| AU2017365123B2 (en) | 2022-02-17 |
| FI3544972T3 (fi) | 2023-06-02 |
| MX389806B (es) | 2025-03-20 |
| CN110234638A (zh) | 2019-09-13 |
| CN110234638B (zh) | 2022-10-21 |
| MX2019006220A (es) | 2019-10-07 |
| HUE061945T2 (hu) | 2023-09-28 |
| PT3544972T (pt) | 2023-06-20 |
| TWI720272B (zh) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL300869B1 (en) | Ligands containing a targeting factor, compositions containing them and uses thereof | |
| IL266962B (en) | Heteroarylphenoxy benzamide kappa opioid ligands, preparations containing them and their uses | |
| IL274297A (en) | Pyrazolo-piperidine-converted indole-2-carboxamides, preparations containing them and their uses | |
| SG11202002218VA (en) | Pyrazolopyrimidinone compounds and uses thereof | |
| IL253433A0 (en) | Binders - tnfrsf and their uses | |
| SG11202002967SA (en) | Integrin ligands and uses thereof | |
| HUE057087T2 (hu) | TIGIT-hez kötõdõ ágensek és alkalmazásaik | |
| GB201714745D0 (en) | New compounds and uses | |
| IL246987A0 (en) | Heteroaryl amides, preparations containing it and their uses | |
| GB201714734D0 (en) | New compounds and uses | |
| GB201714740D0 (en) | New compounds and uses | |
| IL255751B (en) | Preparations of benzamide compounds and their uses | |
| IL297652B2 (en) | Compositions containing methylphenidate prodrugs, processes for their preparation and use | |
| IL253705A0 (en) | Converted triazoles, preparations containing them and their uses | |
| GB201714736D0 (en) | New compounds and uses | |
| EP3393518C0 (en) | ANTIMYCOTIC | |
| IL247921A0 (en) | Glutaminase inhibitor compounds, preparations containing them and their uses | |
| PT3106160T (pt) | Composição de combinação compreendendo huperzina | |
| GB201712110D0 (en) | New compounds and uses | |
| HRP20211776T8 (hr) | Ligandi za integrin alfavbeta6, njihova sinteza i upotreba | |
| GB201603591D0 (en) | Improved promotors and compositions | |
| IL255042A0 (en) | Amphiphilic compounds, their preparations and uses | |
| IL256252B (en) | Imidazodiazepine compound, preparations containing it and its uses | |
| GB201714777D0 (en) | Agent | |
| HK40015851A (en) | Heteroarylphenoxy benzamide kappa opioid ligands |